Wedbush ups Endocyte (ECYT) price target to $20 from $16 citing future cash flows from potential...


Wedbush ups Endocyte (ECYT) price target to $20 from $16 citing future cash flows from potential cancer drug Vintafolide which is pending approval in Europe. Baird upgraded the stock earlier in the week with similar comments. Shares +1.9% premarket. 

Comments (1)
  • Bill Swiggart
    , contributor
    Comments (185) | Send Message
     
    Nice upwelling from small catalyst.
    27 Mar 2013, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs